Speciality: Dermatology
Description:
A warm welcome to all the medical professionals in this interesting session on treatment of hidradenitis suppurativa with biologics.
Hidradenitis Suppurativa (HS) is a chronic skin condition characterized by painful, inflamed nodules and abscesses, often in areas like the armpits, groin, and under the breasts. For patients with moderate to severe cases, traditional treatments like antibiotics and steroids may not be enough. This is where biologic therapies have shown promise.
Biologics are advanced medications that target specific parts of the immune system, which play a key role in the inflammation seen in HS. One of the most commonly used biologics for HS is adalimumab, a TNF-alpha inhibitor. By blocking the inflammatory signals, it helps reduce the frequency and severity of flare-ups.
Clinical trials and real-world evidence have demonstrated the effectiveness of biologics in reducing both pain and the number of lesions in HS patients. These therapies also help prevent new lesions from forming, offering a lifeline for those who have not responded to conventional treatments.
However, biologic treatments are not without risks. They can lower the immune system's ability to fight infections, so patients must be closely monitored. Despite these risks, for many living with the debilitating symptoms of HS, biologics provide much-needed relief and significantly improve their quality of life.
Therefore, get an overall knowledge treatment of hidradenitis suppurativa with biologics. Listen to the webinar, grab the shared knowledge, and follow Hid
See More Webinars @ Hidoc Webinars
1.
A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.
2.
Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment
3.
Racial differences seen in epigenetic age acceleration in childhood cancer survivors
4.
ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer
5.
Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?
1.
Transforming Cancer Care: Metrics, Informatics, Equity, and Real-World Evidence
2.
The Statistical Imperative: Navigating Trends, Precision, and Innovation in Gynecologic Oncology 2025
3.
Precision Era in Pediatric Oncology, from Genomic Breakthroughs to Lifelong Learning
4.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
5.
How to Prevent Tumor Lysis Syndrome in Cancer Patients
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
2.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
3.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
5.
Navigating the Complexities of Ph Negative ALL - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation